- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Spectrum Pharmaceuticals Shares Plummet After Receiving Complete Response Letter from FDA
Spectrum Pharmaceuticals (NASDAQ:SPPI) stock dropped over 20%, after the company announced that it received a Complete Response Letter from the the US Food and Drug Administration relating to its EVOMELA injection drug.
Spectrum Pharmaceuticals (NASDAQ:SPPI) stock dropped over 20%, after the company announced that it received a Complete Response Letter from the the US Food and Drug Administration relating to its EVOMELA injection drug.
According to a press release:
Shares in Spectrum Pharmaceuticals (“Spectrum” or the “Company”) (NASDAQ: SPPI) have plunged over 20% today after the company announced that it received a Complete Response Letter from the United States Food and Drug Administration (“FDA”) related to the company’s EVOMELA injection drug. An FDA Complete Response Letter informs companies that the FDA cannot approve a new drug application as submitted.
In the months prior to today’s news, the Company and its officers made numerous statements about EVOMELA, including statements reflecting the company’s belief that the pending application before the FDA would be successful, and that EVOMELA would contribute to Spectrum’s revenue in late 2015. As such, the FDA’s Complete Response Letter came as a complete surprise to investors.
Block & Leviton LLP is investigating the Company and certain of its officers and directors to learn the facts behind the company’s EVOMELA application, its statements about the drug’s approval process, and the FDA’s subsequent rejection of the company’s new drug application. The firm is also investigating whether any insiders at Spectrum profited from alleged misstatements made about EVOMELA in the weeks and months prior to today’s announcement.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.